Investing in Genomics

Klarna files for NYSE IPO after return to profit, Stada postpones mega German listing, and Quantum Base is coming to AIM.

CoreWeave cuts deal with Open AI ahead of anticipated IPO, Hinge Health files in New York and Venture Global craters.

Which Canadian stocks look like they can weather the trade war with the US while still providing investors with a decent return in 2025?

The Worldwide Healthcare Trust celebrates 30 years this year but it's the next 30 years that look really exciting

One Health to transition from Aquis to AIM in March seeking greater liquidity as raises £8m to build its first surgical hub

Tristel sees strong performance as it continues to focus on opening up new high-growth overseas markets under new CEO Matt Sassone

Feedback hopes capital reorganisation and new funding will help flagship product, Bleepa's penetration into NHS. Buoyed by inclusion in ERF.

UK life sciencies stock ProBiotix Health has secured what it is calling an important new supply agreement in East Asia.

Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis.

Shares in Novo Nordisk were slumping over 2H of 2024, but has this now created a buying opportunity for investors?

Avon Protection looks like one of the best quality stocks on the LSE at the moment, driven partly by fund manager love.

Bitcoin mania and bullishness in the artificial intelligence sector saw UK traders increase their positions in some popular stocks.

Association of Investment Companies' members tip healthcare, technology and North America as the best-performing sectors for 2025

Seven & i holdings in Japan considers IPO of US assets, biotech companies could be coming back to the market, and a Chicago casino.

We take a closer look at Spectrum X, a UK biotech company which could list next year, and is currently taking on pre-IPO investment.

Benchmark has had a challenging year, but the disposal of its Genetics division sparks a new direction and return of capital to shareholders

Pila Pharma's stock has been bid up over 140% since the start of the year as it pushes ahead with research into Type 2 diabetes treatment.

Saxo Bank has published its annual list of outrageous predictions for 2025 to illustrate some of the uncertainties that could affect markets

Monzo CFO appointment sparks IPO expectations, CoreWeave aims for $35bn valuation in 2025 IPO, Odyssey Therapeutics meets investors pre-IPO.

This week we are tipping a China-based pioneer in healthcare devices which you can wear to keep track of essential readings.

One Health Group improves earnings and expects to exceed its previous year-end forecast following resolution of the NHS junior doctors' strike

Canadian miner Brazil Potash aims to get an IPO away in New York, while drug maker Apotex may test market next year.

Fresh from our tour of Japan, we look at five of the top large cap stocks currently trading on the Tokyo Stock Exchange.

The integration of AI into drug discovery is reshaping the biotech and healthcare landscape. Here's how you can invest in these advancements

Biotech company Septerna is coming to NASDAQ, Swiggy cuts its IPO valuation and Hong Kong is back in business with Horizon Robotics IPO

Tecan Group's share price continues to fall, but is this true of the rest of the healthcare sector in Switzerland?

Concerns still swirl around the Cerebras IPO due to the absence of the big tech banks, while London gets ready for Applied Nutrition.

Oxford Biodynamics reports increased orders for prostrate cancer test, but high cash-burn leads to strategic review and cost cutting measures

Perimeter Medical Imaging has a major sugar daddy but investors have been worried about his commitment to the stock: is he still on board?

Ryan Reynolds' ad company sits down with Morgan Stanley to talk IPO plans, while a $200m healthcare SPAC hits the market.

Ocean Harvest sees a disappointing first half but successful trials and new finance point to a brighter second half

Animalcare has a transformational year as disposal of Identicare and STEM sees cash position swell to GBP32.9m

Applied Nutrition said it would be seeking to float on the LSE main board at some time in the course of Q4.

Japanese SSD maker Kioxia is relaunching its IPO bid in Tokyo after a four year hiatus, while MBX Biosciences files in the US.

The spread of mpox in Africa is shifting billions into the healthcare sector: here we look at five of the best stocks in healthcare.

Stocks of vaccine makers and manufacturers of testing equipment surge as mpox virus spreads in central Africa.

AQSE-listed cosmetics group Incanthera said it has radically expanded the size of its initial skincare launch in Europe.

ECO Animal Healthcare moves the needle in the right direction as it delivers a positive set of final results

EDX Medical rapidly grows through new capital investment and acquisition. EDX shares offer +100% return over one-year

Massive interest in anti-obesity drugs has driven the share price of Novo Nordisk and Eli Lilly to dizzying heights.

Theracryf poised for growth despite weak share price. Acquisition boosts pipeline expanding into behavioural brain disorders

On this podcast, Paul Major, Investment Manager of Bellevue Healthcare Trust talks to Stuart Fieldhouse about the Healthcare sector

This week we are buying a US large cap health insurance specialist which is using technology to deliver a better experience for customers.

Voyager Life continues a year of progress seeking to diversify its production chain vertically despite two failed acquisitions

ECO Animal Health has published a positive trading update to emerge from the sector's dark cloud with analysts seeing a buying opportunity

Intuitive Investment Group follows a high conviction-led investment strategy which has yielded one-year returns of 120%

Four years since the start of the Covid-19 pandemic, are the UK's two Big Pharma players going to be able to continue to compete?

A surge in demand for COVID testing globally is helping to power a record set of numbers from this life sciences company.

Uniphar carries 2023 momentum into the new year, setting itself an ambitious mid-term earnings target of EUR200m.

Tristel reports highest sales and profit in its thirty-year history, including during COVID, when demand for its products was unprecedented.

Oscillate implementing its turnaround strategy, cutting costs, streamlining its investment portfolio and focusing on special situations

This Nordic healthcare provider is arguably one of the biggest and best in the region - can its shares start to reflect that in 2024?

UK retail investors continued to back weight loss drug makers in Q4 while also buying the dip on big names down on their luck

French surgeons complete the implant operation for a CARMAT artificial heart which offers a solution for cardiac tumours patients

Moonfare investors are approaching the New Year cautiously and have continued to diversify into the various private investments it offers.

UK-listed Incanthera has secured a major distribution deal for Switzerland and Austria for its proprietary skincare products.

The Armchair Trader tries to predict what the top five investment sectors will be for 2024. Will they be 'hot' or 'not'?

Moves towards further legalisation of cannabis-based medical products have put the European industry in a prime position.

Indivior expecting results to be ahead of expectations as it clears legal case in US and acquires new licences

Shares in Ginkgo Bioworks have been on a downward trajectory since August, but there is plenty of scope here for a big rally.

Following a recent drop in its share price, we take a closer look at SCYNEXIS and its valuable pipeline of anti-fungal treatments.

Oxford BioDynamics advanced precision medicine testing to transform cancer care and provide doctors with the tools they need

Tristel beats analyst expectations and looks forward to its strongest outlook for 30 years as products gain regulatory approval in America

hVivo is riding the crest of the pharma wave, expanding its Phase Two in vitro human testing facilities and targeting expanded order book

Big news for shareholders in Oxford Biodynamics as its latest prostate cancer screening test looks set to be a game changer.

Gooch and Housego expecting revenues and profits for full year to be ahead of market expectations despite contraction in order book

Abcam founder Jonathan Milner is opposed the deal being lined up by US-listed Danaher, but concerns swirl around listings regime in London.

PHC planning a new product launch each year as it targets revenues of $30m by 2025 with demand for biological agri-treatments set to hit $15bn

Ilika dispatches first revenue-generating micro-battery samples as partnership develops with US meditech manufacturer, Cirtec Medical

We take a look at five of the best healthcare sector stocks in the UK, based off their fundamentals and peer analysis.

US listed managed care company, Molina Healthcare is on the rader this week following a shift in market sentiment

Futura Medical gains FDA approval under De Novo Medical Devices programme for flagship topical erectile dysfunction treatment

New CEO takes the helm at cutting edge AI-driven med-tech venture backed by Social Capital's Chamath Palihapitiya.

Hemogenyx investors wait anxiously as FDA airs concerns on Investigational New Drug application for HEMO-CAR-T blood cancer treatement

We met with what we consider to be a game changing US listed healthcare tech company, developing new imaging solutions for cancer treatment.

TT Electronics maintains strong momentum into 2023, but experiencing supply chain issues and the effect of inflation on components

The European stocks universe is full of some excellent opportunities in the healthcare sector: we love this French device manufacturer.

Avacta sees revenues increase to £9.7m as it progresses its AVA6000 Phase 1 targeted chemotherapy trials and begins inhibitor research

Angle PLC to publish results on Friday. Feeling cautiously optimistic. New partnership with Bio-View potentially offers quick-to-market assay test

Avacta progressing trials of maximum tolerated dose for novel targeted chemotherapy delivery platform. Trials on inhibitor tech progressing

We carry out a deep dive on Aquis Stock Exchange listed UK healthcare provider One Health which is helping the UK to cut into waiting lists

We do a deeper dive on Oxford Nanopore's last set of numbers and ask whether investors should still keep this stock on their radars.

Okyo Pharma plans to delist from LSE in May citing a lack of trading volumes and high costs as the rationale behind the move

UK biotech firm Zura Bio live on NASDAQ using an already listed cash shell in order to access the large US investor market

Spectral MD moving forward on US federal contract to supply AI-driven burns diagnosis equipment as part of BARDA programme

We take our first look at this developer of proprietary and frankly revolutionary technology to support cancer surgeons.

Stifel Funds believe inflation may fall faster than many expect. We take a look at their views on another five fund sectors in that scenario

GSK stock looking cheap as pharma giant fends off litigation in US and business goes through vaccine-driven, post-Haleon transformation

Conviction Life Sciences cancels proposed IPO following subscription extension due to "current market uncertainty”

Ilika secures GBP2.8m funding to develop its Goliath range of solid-state transportation batteries for automotive industry

Ilika signs MoU to licence production of micro-battery in US; progressing towards commercialisation of solid-state transportation batteries

Avacta releases outcome of patient trial for its novel AVA6000 chemotherapy treatment. Excellent results; shares rally strongly

Shares in London-listed biotech stock rallied as governments brought in testing for travellers coming from China.

With many analysts expecting a recession in 2023, we look at some of the sectors which could still do well next year.

Conviction Life Sciences delays IPO to the end of January as investor market slows down for Christmas break.

Conviction Life Sciences to list on the LSE this week to raise GBP100m to invest in a portfolio of innovative smaller biotech companies

News of Biogen's Lecanemab breakthrough on Alzheimer's has massively boosted investor interest in companies with R&D in the space.

Genedrive sees losses widen to GBP4.7m and revenues decline 93% as Covid-19 test licenced too late amid time delay for adoption

BioNTech stock is way down from its pandemic highs, but our analysis shows revenue momentum is picking up sharply.

GSK share price continues to languish in 1,200p to 1,800p as market remains unimpressed by management, but is the company undervalued?

Haleon has a lot going for it in the wake of its de-merger from GSK, but can the management team deliver value to investors?

We run some peer analysis on the Pfizer stock in the wake of this week's numbers and look at its latest drug trials.

Bioventix revenues up 7% year-on-year as Dollar strength supports revenue streams. Sales of heart and Vitamin D assays support growth

WuXi Biologics has been busy buying back stock in Hong Kong: we look behind the success story of this drugs R&D specialist.

NMC Healthcare heads off attempt by Noor Capital to get Dubai court to enforce a judgement of debt in its favour.

We look at the data underpinning the solid rise in this large cap healthcare technology stock, which we are buying this week.

We caught up with the management team at Psyence Group just ahead of their announced Phase II trials in the UK.

We launch Series 3 of our podcast by interviewing Merlin Piscitelli of Datasite on the state of play in biopharma M&A.

Dechra Pharmaceuticals prospects continue to look bright with its successful acquisition strategy. But is it a bit expensive right now?

We are back in the global healthcare market this week, a sector which continues to yield some trend-beating stocks for the canny investor.

This week's tip is a small cap German biotech with very sound financials that has attracted the attention of BioNTech.

Haleon shares have seen a tumultuous first few months on the stock market with Zantac litigation and huge debts clouding the stock

TT Electronics bounces back after lockdown, reporting double pre-pandemic order book and operating profits up 4%

Sources close to SpectrumX confirmed it is sill planning an IPO as the company announced manufacturing partnership.

Haleon debuts on London Stock Exchange as GSK spins off its consumer pharma business, but listing considered an underwhelming disappointment

AIM-listed biotech firm wins significant dispute with UK government over unpaid bill for testing equipment.

We met with the management team of biotech firm Psyence Group which is developing an organic solution for extreme anxiety.

Life is returning to some undervalued names in the European biotech and healthcare market - we survey some of the possible leaders.

Johnson and Johnson stock has been resisting the broader equities sell off, but can it go much higher we wonder?

James Coffey runs his ruler over this digital imaging tech player and looks at its prospects as the COVID testing frenzy dies down.

Massive volume in ImmuPharma stock yesterday following news that it has progressed phase III trials of its lupus treatment.

Big news for Sareum Holdings on Monday has rallied the share price back to levels last seen at the start of the year.

On this week's podcast we interview Dallas Webb, senior portfolio manager on the listed Swiss $4.5bn fund BB Biotech.

Shares in CareTech Holdings have moved off their late January lows, but with competing bids being submitted, is it already too expensive?

Selin Bucak puts molecular diagnostics company Genedrive (LSE:GDR) under the microscope and asks what's driving share price volatility

The global eHealth market continues to grow, driven by rising awareness throughout the pandemic of the benefits offered by digital solutions.

Oxford Nanopore was one of the most exciting listings in London last year, but shares have struggled in Q1. Can it turn things around?

Pioneering biotech stock Ovoca Bio was looking great earlier this month, but Russia exposure seems to have investors heading for the exit

Ivor Campbell, Chief Executive of Campbell Snedden, reviews the reasons behind the fall of Omega Diagnostics' share price. What next?

Cizzle Biotechnology shares were up over 40% in trading on Thursday on news of a development and distribution deal in China.

Listed Swiss investment company BB Biotech is proposing to raise its dividend at its next AGM, despite a tough year for the sector.

Selin Bucak looks at protective equipment maker Avon Protection as it makes an effort to turn itself around.

Specialist developer of blood treatments Hemogenyx Pharmaceuticals is seeing renewed investor interest as it commences trial with WuXi.

Covid is clearly here to stay. Yesterday it was the delta variant, today it is Omicron. We've found a few investing ideas on Covid antivirals

Sareum Holdings is hosting its AGM today and reports it is moving forwards to clinical trials of its oral Covid treatment in 2022.

Shares in MyHealthChecked have slipped back down however, despite the news that in the UK, PCR tests are now mandatory for overseas travellers

A letter of intent regarding sub-licencing of a drug has caused the ValiRx share price to fall, when it ought to have gone up.

We talk to the CEO of Sareum Holdings about the progress of the development of COVID treatments as well as other projects in the pipeline.

Sareum Holdings is nearing completion of the pre-clinical phase of SDC-1801 treatment for autoimmune diseases and severe COVID

With a successful IPO behind it, can Oxford Nanopore deliver to investors while still investing heavily into its R&D?

Nanosynth Group has seen shares double in price in the last 10 days following report of deal to sell anti-viral masks to India.

MGC Pharmaceuticals agreement with AMC Holdings holds out prospect for full authorisation of epilepsy and Covid treatments by US FDA

While still trading at a substantial discount, Pantheon International has shrugged off the impact of the pandemic and is realising more cash

Abingdon Health had seen its stock price struggle following IPO and wrangles with government, but now it is booming.

Panel of experts tells Third Bridge that mRNA is best bet in case a Covid variant emerges that bypasses the vaccine.

It's the end of our first season of podcasts and time for summer holidays, so we take the opportunity to go back over the last six months.

For Members Only: a close look at AIM-listed Avacta (LSE:AVCT) and both their COVID-19 lateral flow test and new cancer therapies

NeuroMetrix stock saw major gyrations this month, but the question is whether it is still worth backing for the long term?

Rritual Superfoods has set itself new distribution targets this year having already exceeded its original 10,000 outlet goal.

EnWave Corporation has a proof of concept trial with AstraZeneca affiliate to see if its technology can assist with faster drying of antibodies

Innovation continues as adaptogens specialist announces it will be adding new skin and hair health product to existing range.

Our Nordic correspondent Raine Lahtinen takes a closer look at AIM-listed Finnish biotech company Faron Pharmaceuticals.

We take a closer look at oncology drug developer ValiRx as a new CEO arrvies: is this company looking way too cheap versus its peers?

We run the Irithmics artificial intelligence rule over GlaxoSmithKline shares to find out what long term and short term funds are thinking.

We take a look at AIM-listed DeepVerge, a company that is attracting investor interest thanks to its work looking for Covid in waste water

Giles Coghlan, Chief Currency Analyst at HYCM, explores whether there is any truth to the saying 'sell in May and go away.'

Controversy over the speed of approval of Biogen's Alzheimer's treatment is causing some investors to take profits.

Can this meme stock really go to the moon, is it a short term short squeeze, or has it seen its day already?

Mushroom-based health foods specialist confirms growing purchase orders, in talks with major European distributors including Superdrug.

NetScientific is getting attention thanks to its ProAxsis stake and encouraging progress by its portfolio company PDS Biotechnology

Rritual Superfoods confirms that its products are now available in 2400 retail locations and 10,000 points of distribution

Sareum Holdings sees delays in its auto-immune research but progress on treatment for COVID 19 lung inflammation treatment on schedule

Rritual Superfoods and NEXE are going to work on the development of compostable packaging and a new range of drinks.

Rritual Superfoods is teaming up with health foods specialist Ultimate Sales Canada to support roll out of its natural health brands

Investors in the shares of COVID treatment developer Synairgen are waiting on phase III trial results, but it looks positive to us.

Precipio stock bounded upwards when it announced a deal with Amazon, but investors expecting sustained growth need to be cautious.

Novacyt is debt free and building a globally diversified revenue base but shares have tumbled with the loss of major UK governement contract

Avacta is cautious about being able to repeat its stellar share price performance of 2020, but its results speak for themselves.

For this Podcast, we speak with Ailsa Craig of International Biotechnology Trust which concentrates its activity in the biotech sector

Jamaica-based specialist in cutting edge THC R&D for patients is building the foundations for international expansion.

HempFusion's CBD capsules have been used for a landmark study on the effects of cannabidiol on inflammation, a key area of research for pain relief.

While investors are disappointed with its recent dividend, there is more evidence that DiaSorin's non-Covid business lines are coming back to life.

Futura Medical shares have been soaring on the back of EU distribution prospects, but we think there could be more developments to come.

Shares in Creso Pharma have temporarily stopped trading as the company puts together a financing package following announcement of Halucenex deal.

Master Investor Editor in Chief James Faulkner reveals his top pick, Open Orphan, for this year’s ISA allowance as the tax year draws to a close

We anticipated demand for Rritual Superfoods stock when it first came to the market - now the company is listing shares in Germany too.

As millions more people receive vaccines against COVID, some fund managers are comparing life sciences with Big Oil in terms of its future importance.

Renishaw Group has a unique culture and a range of products that will only increase in demand. It looks to be in good shape for its new owner

Braveheart is not a one trick pony and is already earning the love of investors with some spectacular dividend pay outs from its successful disposals.

There is likely to be huge investment by governments and corporates in pandemic prevention in the years to come but which areas should they focus on?

Omega Diagnostics shares are up 36% in a month following selection by the UK government as one of three UK companies to work on a vital rapid COVID-19 test

The recent success of new cannabis listings in London demonstrate strong investor appetite, but stocks need to be clear on their focus.

Ocugen has seen its share price fly on the back of hopes that it can get an Indian Covid vaccine through the US regulatory approvals process.

Scancell Holdings saw its share price rocket today on news that it is working to deploy a vaccine to cope with a range of mutations in 2022.

Over £1 billion was raised by life sciences companies on AIM last year, driven by massive demands for new virus diagnostics technologies, says finnCap.

Senseonics has seen volumes and its share price spike +230% in the last few days as it has signed a major new deal with a healthcare provider.

CBD wellness specialist HempFusion is up already following its IPO on 6 January and has now reported further USDA Organic certifications for its products.

Biotech specialist has already created plenty of excitement among investors with its work in the area of nasal sprays for coronavirus treatment.

Moderna is widely expected to win regulatory approval and mega bucks for its Covid-19 vaccine that could help put an end to the global pandemic. But this stock is not for the faint hearted

Recent legislative moves in Congress and the UN seem to be paving the way for a boom year in 2021 for the cannabis sector.

We take a look at the prospects for drug giant Pfizer as it nears the finishing post to roll out a vaccine for the coronavirus.

Omega Diagnostics' stock is slipping as its tests come under fire in the British Medical Journal and a major shareholder exits.

It's not over for COVID testing specialist Novacyt - despite the crash in its share price, there could still be plenty of demand for its science in 2021.

We take a closer look at biotech stock 4D Pharma, a fast moving play in the area of live biotherapeutics that is collaborating with Merck.

Sareum Holdings has received conditional approval for a UK government grant, but investors seem disappointed with the level of funding.

Moderna shares seem to be facing headwinds in September, prompted by concerns over vaccine delivery and patent filing transparency.

Genedrive shares have dropped from their May highs as investors have become impatient for results from its on site speed testing tech for COVID

We check in on two biotech stocks we covered early in the pandemic - how do they stack up and what are they working on now?

Testing specialist Genedrive has been in the wilderness for 13 years but the coronavirus has given its technology a chance to shine.

Omega Diagnostics has seen a huge surge in its stock price over the last few weeks, not slowed down by the exercise of further employee stock options.

We follow up on our original note on Anglo-French biotech stock Novacyt, which has been focusing on expanding its coronavirus testing capabilities

AstraZeneca has added 22% to its share price value since 16 March - apart from COVID-19, is there anything else driving investor interest?

UK drugs developer has started live trials with coronavirus patients of a treatment already proven with asthma sufferers.

Our Nordic analyst gets steamed about the Finnish fascination with the sauna and how one sauna stock is taking the world by storm.

Peter Watson reviews the news to bring you two of his favourite stories each day. Today he talks about German pharmaceutical group Bayer and motor dealership Pendragon

Indivior shares: With results duenext week, investors will be looking to forecasts for the current financial year, specifically the extent of the hit to sales of Suboxone

Given that the company said that it now expects a ‘period of sustained growth for years to come’ there is going to be a lot of pressure on Thursday’s full year results

Takeda shareholders will be voting on Wednesday on an offer to buy Ireland's Shire in an acquisition that is being…

Shares fall almost 4% lower after US group Allergan declares it would not make an offer

GSK shares have outperformed the FTSE 100 since the Great Financial Crisis - is this a share for your ISA?

The market will be looking for something special from Reckitt Benckiser this week, but we fear it will be sadly disappointed.

With the last major correction in stocks a decade ago, we are due a market crash as valuations continue to rise

Danish pharma company upsets shareholders by suspending dividend to invest more in key US market.

All eyes are on new Roche treatment as majority of UK brokers call Shire Pharmaceuticals stock a buy

GSK shares are under pressure as investors lose confidence in the pharma giant's ability to maintain it's dividend yield at current levels

The NMC Health share price has risen 98% in just one year. We look at the fundamentals to find out if this performance can continue

The healthcare REIT sector is considered to be a solid long term investment, particularly as the need to accommodate an ageing population in the US increases

Our pursuit of growth stocks has led us to Healthcare provider, NMC Health PLC. Here's why